Hospitalisation for heart failure and death in new users of SGLT-2 inhibitors in patients with and without cardiovascular disease: the CVDREAL study

被引：0
|
作者：
Cavender, M. A. [1 ]
Norhammar, A. [2 ]
Birkeland, K. I. [3 ,4 ]
Jorgensen, M. E. [5 ]
Wilding, P. [6 ]
Khunti, K. [7 ]
Fu, A. Z. [8 ]
Bodegard, J. [9 ]
Blak, B. [10 ]
Wittbrodt, E. T. [11 ]
Thuresson, M. [12 ]
Fenici, P. [13 ]
Hammar, N. [2 ,14 ]
Kosiborod, M. [15 ,16 ]
机构：
[1] Univ N Carolina, Chapel Hill, NC USA
[2] Karolinska Inst, Stockholm, Sweden
[3] Univ Oslo, Oslo, Norway
[4] Oslo Univ Hosp, Oslo, Norway
[5] Steno Diabet Ctr Copenhagen, Gentofte, Denmark
[6] Inst Ageing & Chron Dis, Liverpool, Merseyside, England
[7] Univ Leicester, Leicester, Leics, England
[8] Georgetown Univ, Med Ctr, Washington, DC 20007 USA
[9] AstraZeneca, Oslo, Norway
[10] AstraZeneca, Luton, Beds, England
[11] AstraZeneca, Wilmington, DE USA
[12] Statisticon AB, Uppsala, Sweden
[13] AstraZeneca, Cambridge, England
[14] AstraZeneca Gothenburg, Molndal, Sweden
[15] St Lukes Mid Amer Heart Inst, Kansas City, MO USA
[16] Univ Missouri Kansas City, Kansas City, MO USA
来源：
DIABETOLOGIA | 2017年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
88
引用
收藏
页码：S41 / S41
页数：1
相关论文
共 50 条
  • [31] SGLT-2 inhibitors for treatment of heart failure in patients with and without type 2 diabetes: A practical approach for routine clinical practice
    Giaccari, Andrea
    Pontremoli, Roberto
    Filardi, Pasquale Perrone
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2022, 351 : 66 - 70
  • [32] Cardiovascular Outcomes with SGLT-2 inhibitors in patients with heart failure with or without type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials
    Singh, Awadhesh Kumar
    Singh, Ritu
    DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2021, 15 (01) : 351 - 359
  • [33] Have SGLT-2 inhibitors DELIVERed an EMPhatic win in heart failure and chronic kidney disease?
    Singh, Awadhesh Kumar
    Singh, Akriti
    Singh, Ritu
    EXPERT OPINION ON PHARMACOTHERAPY, 2025, 26 (04) : 457 - 472
  • [34] SGLT-2 inhibitors and mortality among patients with heart failure with reduced ejection fraction: linked database study
    Svanstrom, Henrik
    Mkoma, George Frederick
    Hviid, Anders
    Pasternak, Bjorn
    BMJ-BRITISH MEDICAL JOURNAL, 2024, 387
  • [35] Prescribing patterns of SGLT-2 inhibitors for patients with heart failure: A two-center analysis
    Chakrala, Teja
    Prakash, Roshni O.
    Kim, Justin
    Gao, Hanzhi
    Ghaffar, Umar
    Patel, Jaymin
    Parker, Alex
    Dass, Bhagwan
    AMERICAN HEART JOURNAL PLUS: CARDIOLOGY RESEARCH AND PRACTICE, 2023, 28
  • [36] When should we consider SGLT-2 inhibitors in patients with acute decompensated heart failure?
    Sharma, Aditya
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 2024, 91 (04) : 208 - 208
  • [37] When should we consider SGLT-2 inhibitors in patients with acute decompensated heart failure?
    Badwan, Osamah Z.
    Braghieri, Lorenzo
    Skoza, Warren
    Agrawal, Ankit
    Menon, Venu
    Tang, W. H. Wilson
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 2024, 91 (01) : 47 - 51
  • [38] Comment on SGLT-2 inhibitors for treatment of heart failure in patients with and without type 2 diabetes: A practical approach for routine clinical practice
    Dogar, Mata-e-Alla
    Azeem, Bazil
    Asim, Rabia
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2023, 390
  • [39] SGLT-2 inhibitors in heart failure: real world experience in a chronic heart failure care unit
    Ines Barradas Da Silva, M. Maria
    Duarte, F.
    Castro, J.
    Oliveira, L.
    Serena, C.
    Fontes, A.
    Monteiro, A.
    Machado, C.
    Dourado, R.
    Santos, E.
    Pelicano, N.
    Pacheco, M.
    Tavares, A.
    Martins, D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 : 204 - 204
  • [40] Double Edged Sword: SGLT-2 Inhibitors in the Immunosuppressed Heart Failure Patient
    Brown, Christina
    Addis, Jessica
    Mohamed, Fazad
    CIRCULATION, 2023, 148
12345